名称：原装正品| Human Insulin-like Growth Factor I (hIGF-I)
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIGF-I. All lots are greater than 98% pure. The ED50 of each lot is between 2-8 ng/ml. Most circulating endocrine acting IGF-I is produced by hepatocytes, and paracrine or autocrine acting IGF-I is produced by defined cell types within specific tissues.
Recombinant human IGF-I (hIGF-I) Gly49-Ala118 (Accession #P01343) was produced in E. coli at Cell Signaling Technology. IGF-I activity is regulated by one or more of the six extracellular IGF-binding proteins (IGFBPs). The expected amino-terminal MGPET of recombinant hIGF-I was verified by amino acid sequencing.
DTT-reduced and non-reduced protein migrate as 6 kDa polypeptides. Recombinant hIGF-I has a Met on the amino terminus and has a calculated MW of 7,785.
The bioactivity of recombinant hIGF-I was determined in a cell proliferation assay using primary human dermal fibroblasts. IGF-I and IGFIR are frequently expressed by cancer cells and may contribute to the proliferation and viability of a number of cancer types (1,2). Endotoxin: Less than 0.01 ng endotoxin/1 μg hIGF-I.